AiCuris and Max Planck Institute of Molecular Physiologyjoin forces in the field of anti-infectives

April 18, 2018
AiCuris Anti-infective Cures GmbH

Wuppertal and Dortmund, Germany, April 18, 2018 - AiCuris Anti-infective Cures GmbH, a leading company in the discovery and development of innovative drugs targeting infectious diseases and the Max Planck Institute of Molecular Physiology (MPI) in Dortmund, Germany, have entered into a collaborative agreement to identify novel compounds for the treatment of viral and bacterial infections.

Press Release available here: